Skip to content

Study · Observational study · n = 84 · 2026

4 results

Retrospective comparison of the clinical effects of oral semaglutide and SGLT2 inhibitors treatment in patients with type 2 diabetes.

Omori Y, Usui R, Yamazaki Y, Kuwata H, Hamamoto Y, Yamada Y, Seino Y

Journal of diabetes investigation20 Jan 2026

PMID41555812 (opens in a new tab)PMCIDPMC12950920 (opens in a new tab)DOI10.1111/jdi.70240 (opens in a new tab)PepBankPUB-41555812
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, oral semaglutide reduced HbA1c by 0.88% at 6 months, similar to SGLT2 inhibitors.

    In plain wordsIn adults with type 2 diabetes, oral semaglutide lowered HbA1c over 6 months, about the same as SGLT2 inhibitors.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change at 6 months
    Study

    n = 84

    Comparator
    SGLT2 inhibitors
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −0.88%
    oral semaglutide, 6 months

    Source sentences

    Summary
    reductions in glycated hemoglobin (HbA1c) (semaglutide: -0.88 ± 0.14%; P < 0.01, and SGLT2is: -0.86 ± 0.06%; P < 0.01, at 6 months)
    1 context sentence
    Summary · context
    Patients with type 2 diabetes who were initiated on oral semaglutide or SGLT2is and continued treatment for 6 months or more were retrospectively analyzed and compared.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, oral semaglutide reduced body weight by 2.58 kg at 6 months, similar to SGLT2 inhibitors.

    In plain wordsIn adults with type 2 diabetes, oral semaglutide lowered body weight over 6 months, about the same as SGLT2 inhibitors.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change at 6 months
    Study

    n = 84

    Comparator
    SGLT2 inhibitors
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Measurements

    Body weight change
    −2.58 kg
    oral semaglutide, 6 months

    Source sentences

    Summary
    body weight (semaglutide: -2.58 ± 0.37 kg; P < 0.01, and SGLT2is: -2.30 ± 0.18 kg; P < 0.01, at 6 months)
    1 context sentence
    Summary · context
    Patients with type 2 diabetes who were initiated on oral semaglutide or SGLT2is and continued treatment for 6 months or more were retrospectively analyzed and compared.
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, oral semaglutide reduced fat mass by 2.20 kg at 6 months, similar to SGLT2 inhibitors.

    In plain wordsIn adults with type 2 diabetes, oral semaglutide lowered body fat mass over 6 months, about the same as SGLT2 inhibitors.

    Peptide
    Semaglutide
    Outcome
    DecreaseFat mass change at 6 months
    Study

    n = 84

    Comparator
    SGLT2 inhibitors
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Measurements

    Fat mass change
    −2.2 kg
    oral semaglutide, 6 months

    Source sentences

    Summary
    fat mass (semaglutide: -2.20 ± 0.50 kg; P < 0.01, and SGLT2is: -1.93 ± 0.44 kg; P < 0.01, at 6 months)
    1 context sentence
    Summary · context
    Patients with type 2 diabetes who were initiated on oral semaglutide or SGLT2is and continued treatment for 6 months or more were retrospectively analyzed and compared.
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, oral semaglutide did not significantly change skeletal muscle mass at 6 months, whereas SGLT2 inhibitors significantly reduced it.

    In plain wordsIn adults with type 2 diabetes, oral semaglutide did not significantly change muscle mass over 6 months, while SGLT2 inhibitors reduced it.

    Peptide
    Semaglutide
    Outcome
    No significant changeSkeletal muscle mass change at 6 months
    Study

    n = 84

    Comparator
    SGLT2 inhibitors
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Measurements

    Skeletal muscle mass change
    −0.1 kg
    oral semaglutide, 6 months

    Source sentences

    Summary
    On the other hand, there was a significant reduction in skeletal muscle mass only in the SGLT2is group (semaglutide: -0.10 ± 0.30 kg; P = 0.74, and SGLT2is: -0.40 ± 0.14 kg; P < 0.01 at 6 months).
    1 context sentence
    Summary · context
    Patients with type 2 diabetes who were initiated on oral semaglutide or SGLT2is and continued treatment for 6 months or more were retrospectively analyzed and compared.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.